Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer-Reference-Cited by-同舟云学术

Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer

Published:2019-05 Issue:3 Volume:20 Page:201-207
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Grangeon Mathieu,Tomasini Pascale,Chaleat Solene,Jeanson Arnaud,Souquet-Bressand Maxime,Khobta Nataliya,Bermudez Julien,Trigui Youssef,Greillier Laurent,Blanchon Marilyne,Boucekine Mohamed,Mascaux Celine,Barlesi Fabrice

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference23 articles.

1. Cancer statistics, 2015;Siegel;CA Cancer J Clin,2015

2. Global cancer statistics;Jemal;CA Cancer J Clin,2011

3. Immune checkpoint blockade;Naidoo;Hematol Oncol Clin North Am,2014

4. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC);Spigel;J Clin Oncol,2015

5. KEYNOTE-024: phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1);Brahmer;J Clin Oncol,2015

Cited by 147 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC;Immunotherapy;2024-09-13

2. PCCA variant rs16957301 is a novel AKI risk genotype-specific for patients who receive ICI treatment: Real-world evidence from All of Us cohort;2024-06-20

4. The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors;Japanese Journal of Clinical Oncology;2024-05-20

5. Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis;Cancer Immunology Research;2024-05-20